Dyanavel XR
Drug
Tris Pharma Inc
Total Payments
$5.0M
Transactions
102,049
Doctors
21,555
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 22,159 | 8,433 |
| 2023 | $520,027 | 21,964 | 7,885 |
| 2022 | $338,692 | 14,390 | 5,655 |
| 2021 | $160,563 | 7,527 | 3,031 |
| 2020 | $101,691 | 5,307 | 2,369 |
| 2019 | $681,395 | 7,120 | 2,972 |
| 2018 | $1.1M | 13,151 | 5,077 |
| 2017 | $796,917 | 10,431 | 4,588 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2.0M | 99,394 | 39.4% |
| Honoraria | $1.7M | 1,066 | 34.8% |
| Unspecified | $950,786 | 14 | 19.0% |
| Travel and Lodging | $326,834 | 1,519 | 6.5% |
| Consulting Fee | $9,371 | 5 | 0.2% |
| Gift | $700.00 | 35 | 0.0% |
| Education | $480.00 | 16 | 0.0% |
Payments by Type
General
$4.0M
102,035 transactions
Research
$950,786
14 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single Center, Flexible-Dose, 8-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study the Efficacy Of Dyanavel XR In Treating Co-Occurring Fatigue In Adults With Attention Deficit/Hyperactivity Disorder (ADHD) | Tris Pharma Inc | $543,594 | 1 |
| Dynavel XR Extended-Release Oral Suspension in the Treatment of Children with ADHD Al Laboratory School Study | Tris Pharma Inc | $190,146 | 1 |
| A Retrospective Real World Data Analysis of Hypothesized Causal Relationships of Dyanavel XRs Lower Rate of Supplementation by an Instant-Release Stimulant | Tris Pharma Inc | $143,450 | 1 |
| TRI 102-PPK-300 A single dose open label Pharmacokinetic study of Dyanavel XR extended release oral suspension in children 4-5 years with ADHD | Tris Pharma Inc | $62,096 | 0 |
| TRI 102-PPK-300 A single dose open label Pharmacokinetic study of Dyanavel XR amphetamine extended release oral suspension in children 4-5 years with ADHD | Tris Pharma Inc | $11,500 | 0 |
Top Doctors Receiving Payments for Dyanavel XR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Psychiatry | Rochester Hills, MI | $705,229 | 33 |
| , M.D | Psychiatry | Northbrook, IL | $280,843 | 524 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $241,657 | 91 |
| Suvrat Bhargave | — | Tyrone, GA | $200,184 | 427 |
| , MD | Child & Adolescent Psychiatry | Houston, TX | $167,063 | 276 |
| , M.D | Psychiatry | Houston, TX | $115,306 | 310 |
| , M.D | Child & Adolescent Psychiatry | Houston, TX | $91,664 | 136 |
| Amanda Murray | — | Dothan, AL | $73,638 | 8 |
| , M.D | Developmental - Behavioral Pediatrics | Tampa, FL | $72,793 | 150 |
| , DO | Psychiatry | Orlando, FL | $65,728 | 203 |
| , MD | Anesthesiology | Indianapolis, IN | $62,215 | 190 |
| , M.D | Pediatrics | Rockville, MD | $61,015 | 221 |
| , M.D | Child & Adolescent Psychiatry | Troy, MI | $48,099 | 112 |
| Derek Ott | — | Beverly Hills, CA | $43,211 | 171 |
| , M.D | Pediatrics | Mobile, AL | $41,411 | 207 |
| , M.D | Developmental - Behavioral Pediatrics | Traverse City, MI | $40,348 | 105 |
| , MD | Child & Adolescent Psychiatry | San Antonio, TX | $38,830 | 88 |
| , MD | Child & Adolescent Psychiatry | Plano, TX | $38,136 | 125 |
| , MD | Psychiatry | Franklin, TN | $33,262 | 92 |
| , MD | Neurology with Special Qualifications in Child Neurology | Plainview, NY | $33,005 | 135 |
| , M.D | Developmental - Behavioral Pediatrics | Scottsdale, AZ | $31,281 | 125 |
| , MD | Psychiatry | Lake Jackson, TX | $29,380 | 43 |
| , M.D | Neurology | Willoughby, OH | $26,358 | 95 |
| , D.O | Student in an Organized Health Care Education/Training Program | Danbury, CT | $25,447 | 66 |
| , M.D | Specialist | Elyria, OH | $25,036 | 65 |
Ad
Manufacturing Companies
- Tris Pharma Inc $5.0M
Product Information
- Type Drug
- Total Payments $5.0M
- Total Doctors 21,555
- Transactions 102,049
About Dyanavel XR
Dyanavel XR is a drug associated with $5.0M in payments to 21,555 healthcare providers, recorded across 102,049 transactions in the CMS Open Payments database. The primary manufacturer is Tris Pharma Inc.
Payment data is available from 2017 to 2024. In 2024, $1.3M was paid across 22,159 transactions to 8,433 doctors.
The most common payment nature for Dyanavel XR is "Food and Beverage" ($2.0M, 39.4% of total).
Dyanavel XR is associated with 5 research studies, including "A Single Center, Flexible-Dose, 8-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study the Efficacy Of Dyanavel XR In Treating Co-Occurring Fatigue In Adults With Attention Deficit/Hyperactivity Disorder (ADHD)" ($543,594).